Head and neck cancer in Styria : An epidemiologic and clinical audit.
Austria
Geographical distribution
Head and neck malignancy
Risk factor
TNM classification
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
29
08
2019
accepted:
03
12
2019
pubmed:
16
1
2020
medline:
18
11
2020
entrez:
16
1
2020
Statut:
ppublish
Résumé
The outcome of patients with cancer of the head and neck is significantly improved by increased interdisciplinary cooperation. The main focus of this study was a comparison of epidemiologic factors (age, sex, origin, staging) of patients with head and neck cancer in Styria, with those for patients throughout Austria. A retrospective data analysis of collected archived tumor board protocols of the Comprehensive Cancer Center (CCC) Graz included the patient's age, sex, area of residence, TNM stage, reasons for inoperability, comorbidities and performance status by ECOG (Eastern Cooperative Oncology Group), was performed. This study focuses on 340 patients who presented with a head and neck malignancy for the first time. In the period from January 2014 to December 2015 a total of 252 men (74.1%) and 88 women (25.9%) with malignant head and neck tumors, were presented in the tumor board for the first time. The mean age at diagnosis was 63.4 years. In 45.5% the patients already demonstrated advanced tumor stages (T4 = 27.9%, T3 = 17.6%). Most newly diagnosed neoplasms were cancers of the oropharynx (24.1%), larynx (19.4%) and oral cavity (18.8%) and 36.5% were considered to be inoperable. Curative and palliative treatments were initiated in 83.2% and 16.9%, respectively. The region of south Styria showed a higher incidence of T3 and T4 tumors of the oropharynx than the average Austrian population. Measures to increase awareness of this problem should be initiated to support general otorhinolaryngologists and general practitioners in detecting oropharyngeal cancers at an earlier stage.
Sections du résumé
BACKGROUND
BACKGROUND
The outcome of patients with cancer of the head and neck is significantly improved by increased interdisciplinary cooperation. The main focus of this study was a comparison of epidemiologic factors (age, sex, origin, staging) of patients with head and neck cancer in Styria, with those for patients throughout Austria.
METHODS
METHODS
A retrospective data analysis of collected archived tumor board protocols of the Comprehensive Cancer Center (CCC) Graz included the patient's age, sex, area of residence, TNM stage, reasons for inoperability, comorbidities and performance status by ECOG (Eastern Cooperative Oncology Group), was performed. This study focuses on 340 patients who presented with a head and neck malignancy for the first time.
RESULTS
RESULTS
In the period from January 2014 to December 2015 a total of 252 men (74.1%) and 88 women (25.9%) with malignant head and neck tumors, were presented in the tumor board for the first time. The mean age at diagnosis was 63.4 years. In 45.5% the patients already demonstrated advanced tumor stages (T4 = 27.9%, T3 = 17.6%). Most newly diagnosed neoplasms were cancers of the oropharynx (24.1%), larynx (19.4%) and oral cavity (18.8%) and 36.5% were considered to be inoperable. Curative and palliative treatments were initiated in 83.2% and 16.9%, respectively.
CONCLUSION
CONCLUSIONS
The region of south Styria showed a higher incidence of T3 and T4 tumors of the oropharynx than the average Austrian population. Measures to increase awareness of this problem should be initiated to support general otorhinolaryngologists and general practitioners in detecting oropharyngeal cancers at an earlier stage.
Identifiants
pubmed: 31940091
doi: 10.1007/s00508-019-01591-y
pii: 10.1007/s00508-019-01591-y
pmc: PMC7445200
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
444-451Références
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
J Natl Compr Canc Netw. 2018 May;16(5):479-490
pubmed: 29752322
BMC Public Health. 2015 Aug 08;15:758
pubmed: 26253077
BMC Cancer. 2015 Dec 23;15:1000
pubmed: 26698112
Oncology. 2016;91(1):13-23
pubmed: 27245686
BMC Cancer. 2014 May 05;14:316
pubmed: 24886308
Health Place. 2012 Jul;18(4):861-8
pubmed: 22445028
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
CA Cancer J Clin. 2017 Jan;67(1):51-64
pubmed: 28076666
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Int J Cancer. 1988 Apr 15;41(4):483-91
pubmed: 3356483
J Community Health. 2012 Apr;37(2):316-9
pubmed: 21786206
Am J Epidemiol. 2013 Sep 1;178(5):679-90
pubmed: 23817919
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD006386
pubmed: 20824847